dimarts, 23 de setembre del 2014

Ivantis adds $25M, eyes U.S. approval for glaucoma micro-stent




Ivantis takes its Series B round to $71 million with another $25 million tranche as it looks to get its Hydrus micro-stent for glaucoma on the U.S. market.






Ivantis today said it added a $25 million tranche to its now $71 million Series B round as the Irvine, Calif.-based company looks to bring its miniature glaucoma scaffold to the U.S. market.




read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1v5r2oF

Cap comentari:

Publica un comentari a l'entrada